Jung et al. utilized the CSNRDARRC peptide (Bld-1) as a targeting ligand to selectively deliver KLA to bladder cancer and examined the activity of Bld-1-KLA hybrid peptide as targeted therapy for bladder tumors with pro-apoptotic peptides. Here, KL is linked to urinary bladder neoplasm.